News2025-03-14T18:43:32+00:00
News
Home»Company»News

News

Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.

1504, 2025

US Food and Drug Administration FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

April 15th, 2025|Biologics Testing, News|

The FDA is phasing out animal testing for monoclonal antibodies and other drugs, turning to AI, lab-grown human tissues, and global safety data to streamline development, cut costs, and improve patient safety...

804, 2025

Breakthrough in CAR-T Cell Therapy Offers Hope for B-ALL Treatment

April 8th, 2025|CAR-T & Other Cell Therapy Testing, Gene & Cell Therapy, News|

A new study offers hope for improving CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL), a cancer with high relapse rates. Researchers have developed an innovative approach involving a TIM-3 decoy that prevents immune evasion by leukemia cells...

204, 2025

Avance Biosciences Plays Key Role in RNA Sequencing for Promising COVID-19 Vaccine

April 2nd, 2025|Biologics Testing, News, Vaccine|

Avance Biosciences contributed critical RNA sequencing to the development of MV-014-212, a novel intranasal COVID-19 vaccine. In preclinical trials, MV-014-212 showed significant promise by reducing viral shedding and eliciting a broad immune response, including protection against multiple variants of concern...

1803, 2025

Empowering Drug Development with CLIA Testing Services

March 18th, 2025|Biologics Testing, CLIA Testing, News|

Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...

1103, 2025

Breakthrough in Genetic Medicine: Beam Therapeutics Shows Potential with BEAM-302 for Alpha-1 Antitrypsin Deficiency

March 11th, 2025|Gene Editing, News, Press Release|

Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...

403, 2025

New RNA-Guided System Uncovered, Offering Promise for Precision Gene Editing Therapies

March 4th, 2025|Gene Editing, News|

TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...

Go to Top